Sabato 27 ottobre 2012 - Pacini Editore

292
dehydration) with which the tissue has been processed. In addition,
considerable money saving may be accomplished, moving
the focus on other necessary spending such as quality control.
Acknowledgments. We wish to thank Prof. TT Sun, D Crawford,
RM Steinman, PJ Martin, R Cardiff, JC Gluckman, D Lane, MF
Greaves and many others for donating antibodies. Lorella Riva,
Angelita Ferri and the whole Laboratory Technician staff contributed
to the project. MCA was supported by a generous grant
from Prof. F. Uggeri.
references
Balaton A J, Drachenberg CB, et al. Satisfactory Performance of Primary
Antibodies Beyond Manufacturers’ Recommended Expiration
Dates. Applied Immunohistochemistry & Molecular Morphology
1999;7:221-5.
Savage EC, DeYoung BR. Antibody expiration in the context of resource
limitation: what is the evidence basis? American Journal of Clinical
Pathology 2010;134:60-4.
Tubbs RR, Nagle R, et al. Extension of useful reagent shelf life beyond
manufacturers’ recommendations. Cell Markers Committee of the
College of American Pathologists. Archives of pathology & laboratory
medicine 1998;122:1051-2.
Vigliani R, Babache N. Primary antisera before and after the expiration
date. Comparative immunohistochemical observations and analysis of
data sheets and labels. Pathologica 2002;94:121-9.
CONGRESSO aNNualE di aNatOmia patOlOGiCa SiapEC – iap • fiRENzE, 25-27 OttOBRE 2012
Antibody Clone Isotype Supplied as Year Source Lab
Keratin aE1 igg1 supernatant 1986 tt Sun gc
Keratin aE3 igg1 supernatant 1986 tt Sun gc
tP53 Pab1801 igg1 supernatant 1987 D crawford gc
EMa E29 igg2a supernatant 1990 Dako cP
Muscle actin HHf35 igg1 RtU 1993
Enzo
pharmaceuticals
cP
cD45R0 Uchl1 igg2a supernatant 1994 Dako cP
cD3 Na Rb RtU 1996 Dako cP
Cd79a Hm57 igg1 supernatant 2000 Dako cP
Fig. 1.
a: Mca holding the 1986 original tubes; B: aE-1, liver; C: aE-3, liver;
d: actin, gut; E: Ki-67, tonsil; f: Cd3, tonsil; G: Cd79a, tonsil; H: Cd34,
tonsil.
Introduction of a routinely new collection
and preparation system for urine cytology:
method and impact evaluation
A. Bondi, R. Rapezzi, S. Negri
U.O. Anatomia, Istologia Patologica e Citodiagnostica. Ospedale Maggiore
Bologna, AUSL Bologna
Background. According to data from the Mortality Registry in
Emilia Romagna Region (1998-2004), almost 500 deaths a year
are due to bladder cancer, of which slightly more than 100 women
and almost 400 men.
The relative risk for the municipality of Bologna is > 1.3 and has
a very uniform distribution, especially among males. It ‘a rare
cancer before age of 40 and increases after 60.
The proposed health intervention has affected the entire province
of Bologna, whose catchment area up to 2008 December 31 consisted
of 1,105,764 inhabitants of which over 900,000 reside on
the district of Bologna AUSL.
The project stems from the need of business planning, rationalization
and control of health care and has involved all stakeholders
actors in the reorganization process, first the 3 Anatomic Pathologies
and the CUP (Unified Booking Centre) service.
The classical method of urine preparation for cytology samples
consists in fresh processing: for each patient were collected three
samples obtained in different days, processed separately.
Materials and Methods. We have designed a cardboard box
with foam housings three cans of 150 ml each, containing 35 ml
of fixative consisting of a mixture of ethanol (> 95%), methanol
(< 3%) and buffered formalin (< 0.5%) (manufacturer Diapath).
The patient adds approximately 100 ml of urine to the fixative
and the box can be stored for up to seven days in cool.
In the laboratory, the three samples are mixed and processed together
on a filtration ramp using a polycarbonate membrane with
5 microns porosity to set up a single cytology preparation stained
with Papanicolou technique.
Results and discussion. In this study we show a comparison
between two years: one (2011) using the new established method
and other (2008) where the sample was collected with the classical
method. The samples are classified according to WHO 2004
(modified for cytology): Inadequate (prepared without transitional
items), Negative (including acute and chronic inflammation
pattern, simple and papillary hyperplasia pattern without atypia),
Hyperplasia with nuclear atypia (mainly papillary),
Suspect (not conclusive for diagnosis of cancer) and Positive
(transitional cell carcinoma and NAS).
For the two periods, the distribution of diagnoses considered
“negative” (no clinical study required) and “atypical / positive”
(further diagnostic tests required), shows no significant deviations
(negative decreased from 90 to 89% and Atypical / Positives
from 8.8 to 8.5%).
Inadequate samples are doubled in 2011. Since the indication
for inadequate samples is the repetition of test, we checked the